At a glance
ClinicalIndex Comparison RecordN/ACompleted· 80 enrolled
Drug / intervention
Xonrid® gel +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Monocenter, Open Label Clinical Investigation on the Treatment With Xonrid®, a Medical Device for the Prevention and Treatment of Radiotherapy-induced Dermatitis, in Breast and Head & Neck Cancer Patients Receiving Curative Treatment.
In Brief
A clinical study evaluating Xonrid® gel and Standard of Care for Radiodermatitis and Quality of Life. Completed, enrolled 80 participants across 1 site.
Detailed Summary
To evaluate the performance of Xonrid® in the prevention and treatment of G2 radiation dermatitis in breast and head \& neck cancer patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRadiodermatitis, Quality of Life
CountriesItaly
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartJun 2017
First PostedAug 2017
Primary CompletionFeb 2019
Study CompletionJan 2020
TodayJul 2026
First PostedAug 21, 2017
Enrollment StartJun 15, 2017
Primary CompletionFeb 20, 2019
Study CompletionJan 22, 2020
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.9 years ago
Interventions
Xonrid® geldevice
Water based gel for the management of toxicity skin symptoms induced by Radiotherapy
Standard of Careother
Standard of care suggested by MASCC' Skyn Toxicity Study Group guidelines